Relationship between the clinical response to adalimumab treatment and serum levels of adalimumab and anti-adalimumab antibodies in patients with psoriatic arthritis

被引：75
|
作者：
van Kuijk, A. W. R. [1 ,2 ]
de Groot, M. [3 ]
Stapel, S. O. [4 ]
Dijkmans, B. A. C. [2 ,5 ]
Wolbink, G. J. [2 ,4 ]
Tak, P. P. [1 ]
机构：
[1] Univ Amsterdam, Div Clin Immunol & Rheumatol, Acad Med Ctr, NL-1105 AZ Amsterdam, Netherlands
[2] Jan van Breemen Inst, Amsterdam, Netherlands
[3] Univ Amsterdam, Dept Dermatol, Acad Med Ctr, NL-1105 AZ Amsterdam, Netherlands
[4] Sanquin Res, Amsterdam, Netherlands
[5] Vrije Univ Amsterdam, Dept Rheumatol, Med Ctr, Amsterdam, Netherlands
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2010年 / 69卷 / 03期
关键词：
RHEUMATOID-ARTHRITIS; CRITERIA; VALIDATION;
D O I：
10.1136/ard.2009.108787
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：624 / U187
页数：2
相关论文
共 50 条
  • [1] Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis
    Bartelds, Geertje M.
    Wijbrandts, Carla A.
    Nurmohamed, Michael T.
    Stapel, Steven
    Lems, Willem F.
    Aarden, Lucien
    Dijkmans, Ben A. C.
    Tak, Paul Peter
    Wolbink, Gerrit Jan
    ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 (07) : 921 - 926
  • [2] NO PREDICTIVE VALUE OF ADALIMUMAB SERUM LEVELS AND ANTI-ADALIMUMAB ANTIBODIES AT TIME OF ADALIMUMAB FAILURE FOR PREDICTION OF RESPONSE TO THE NEXT BDMARD
    Den Broeder, N.
    Ulijn, E.
    Wientjes, M.
    Van Herwaarden, N.
    Meek, I.
    Tweehuysen, L.
    Van der Maas, A.
    Van den Bemt, B.
    Den Broeder, A.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 1388 - 1389
  • [3] Relationship between serum adalimumab levels, incidence of human anti-human antibodies (HAHAs) and clinical response to adalimumab in patients with rheumatoid arthritis (RA)
    Bartelds, G. M.
    Wijbrandts, C. A.
    Nurmohamed, M. T.
    De Vrieze, H.
    Lems, W. F.
    Kammeijer-Rippen, M.
    Aarden, L.
    Dijkmans, B. A. C.
    Tak, P. P.
    Wolbink, G. J.
    ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 : 175 - 175
  • [4] The influence of anti-adalimumab antibodies on adalimumab through levels, TNF-α levels and clinical outcome
    Bodini, G.
    Giannini, E.
    Pellegatta, G.
    Demarzo, G.
    Marabotto, E.
    Furnari, M.
    Baldissarro, I.
    Savarino, V.
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2017, 47 : 88 - 88
  • [5] Detection of Adalimumab and Anti-Adalimumab Levels by ELISA: Clinical Considerations
    Marinari, Barbara
    Botti, Elisabetta
    Bavetta, Mauro
    Spallone, Giulia
    Zangrilli, Arianna
    Talamonti, Marina
    Richetta, Antonio
    Chimenti, Sergio
    Costanzo, Antonio
    DRUG DEVELOPMENT RESEARCH, 2014, 75 : S11 - S14
  • [6] THE INFLUENCE OF ANTI-ADALIMUMAB ANTIBODIES ON ADALIMUMAB THROUGH LEVELS, TNF-α LEVELS AND CLINICAL OUTCOME
    Bodini, G.
    Savarino, V.
    Dulbecco, P.
    Baldissarro, I.
    Savarino, E.
    DIGESTIVE AND LIVER DISEASE, 2015, 47 : E94 - E95
  • [7] The influence of anti-adalimumab antibodies on adalimumab trough levels, TNF-α levels and clinical outcome
    Bodini, G.
    Savarino, V.
    Dulbecco, P.
    Baldissarro, I.
    Savarino, E.
    JOURNAL OF CROHNS & COLITIS, 2014, 8 : S42 - S42
  • [8] Therapeutic drug monitoring of adalimumab in RA: no predictive value of adalimumab serum levels and anti-adalimumab antibodies for prediction of response to the next bDMARD
    Ulijn, Evy
    den Broeder, Nathan
    Wientjes, Maike
    van Herwaarden, Noortje
    Meek, Inger
    Tweehuysen, Lieke
    van der Maas, Aatke
    van den Bemt, Bart J. F.
    den Broeder, Alfons A.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 (07) : 867 - 873
  • [9] Adalimumab trough serum levels and anti-adalimumab antibodies in the long-term clinical outcome of patients with Crohn's disease
    Bodini, Giorgia
    Giannini, Edoardo G.
    Savarino, Vincenzo
    Del Nero, Lorenzo
    Pellegatta, Gaia
    De Maria, Costanza
    Baldissarro, Isabella
    Savarino, Edoardo
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2016, 51 (09) : 1081 - 1086
  • [10] ASSOCIATION OF CLINICAL EFFICACY WITH SERUM LEVEL OF ADALIMUMAB (ADA) AND ANTI-ADALIMUMAB ANTIBODY LEVELS IN PATIENTS WITH EARLY RHEUMATOID ARTHRITIS (RA)
    Avdeeva, A. S.
    Aleksandrova, E. N.
    Novikov, A. A.
    Karateev, D. E.
    Luchihina, E. L.
    Cherkasova, M. V.
    Nasonov, E. L.
    ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 927 - 927
12345